Why the study?
To evaluate and compare the clinical usefulness of plasma ANP and cTnI concentrations for assessing disease severity in dogs with naturally occurring MVD.
Do plasma ANP and cTnI concentrations accurately assess disease severity in dogs with naturally occurring mitral valve disease?
Population
316 dogs with MVD and 40 healthy control dogs
Comparison
MVD stages (B1 vs B2 vs C) and healthy controls
Authors
Loading...
ANP and cTnI may support severity grading in canine MVD; leaves open independent diagnostic utility and requires prospective validation.
Do plasma ANP and cTnI concentrations accurately assess disease severity in dogs with naturally occurring mitral valve disease?
Plasma ANP and cTnI concentrations can be used to assess MVD severity and supplement echocardiographic findings in dogs, though they should not be used independently for diagnosis.
Hori et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: